Tickers

1. Composite Trajectory Verdict

For a commercial-stage biopharmaceutical company with a marketed product (LUPKYNIS) and a development pipeline, the income statement and cash flow statement carry the most weight because they directly reflect product traction, operating leverage, and self-funding capacity; the balance sheet is important primarily as a scorecard of cash accumulation and liability management.

Composite Trajectory: Improving

The annual series shows revenue growing from $175.5M (2023) to $235.1M (2024) to $283.1M (2025) (10-K 2025-12-31, Consolidated Statements of Operations), with operating income swinging from a -$91.7M loss to a $104.9M gain over the same span. Quarterly year-over-year comparisons confirm acceleration: Q2 2026 revenue of $83.2M vs $70.0M in Q2 2025 (+19%) and operating income of $46.3M vs $20.1M (10-Q 2026-06-30, Consolidated Statements of Operations); Q1 2026 revenue of $77.7M vs $62.5M in Q1 2025 (+24%) with operating income of $41.4M vs $21.8M (10-Q 2026-03-31, Consolidated Statements of Operations). Cash from operations rose from -$33.5M (2023) to $44.4M (2024) to $135.7M (2025) (10-K 2025-12-31, Consolidated Statements of Cash Flows) and reached $85.1M in the first half of 2026 vs $45.5M in H1 2025 (10-Q 2026-06-30, Consolidated Statements of Cash Flows). The balance sheet strengthened with cash and investments increasing from $358.5M (Dec 2024) to $398.0M (Dec 2025) to $443.1M (June 2026) despite $213.4M cumulative share repurchases (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A). No dimension shows deterioration; the tax-driven net income spike in 2025 is a one-time benefit, but operating and cash trends are fundamentally improving.

2. Red Flags

• Large one-time tax benefit distorts 2025 net income: Income tax benefit of $173.0M in 2025 from valuation allowance release turned a $114.2M pre-tax income into $287.2M net income, compared to $5.8M net income on $7.4M pre-tax income in 2024 (10-K 2025-12-31, Consolidated Statements of Operations). This non-recurring item inflates the annual net income growth rate.
• Volatile other expense (income), net: Swings from $8.4M expense (2023) to $4.3M income (2024) to $9.5M expense (2025) (10-K 2025-12-31, Consolidated Statements of Operations), then to $6.2M income in Q2 2026 and $0.3M expense in Q1 2026 (10-Q 2026-06-30, Consolidated Statements of Operations; 10-Q 2026-03-31, Consolidated Statements of Operations), driven by foreign exchange remeasurement of the Swiss Franc-denominated finance lease liability and deferred compensation fair value changes.
• Restructuring charges in consecutive years: $23.1M in 2024 and $1.6M in 2025 (10-K 2025-12-31, Consolidated Statements of Operations), with none recorded in Q1 or Q2 2026 (10-Q 2026-06-30, Consolidated Statements of Operations; 10-Q 2026-03-31, Consolidated Statements of Operations), indicating recent cost-structure resets.
• Sharp decline in share-based compensation: SG&A share-based compensation fell from $31.6M (2024) to $12.7M (2025) (10-K 2025-12-31, MD&A SG&A table) and from $4.9M in Q2 2025 to $1.2M in Q2 2026 (10-Q 2026-06-30, SG&A table), partly due to forfeitures from officer departures, which reduces a recurring non-cash expense but may signal workforce turnover.
• Gross margin variability tied to product mix: Gross margin was 88% in both 2024 and 2025 (10-K 2025-12-31, MD&A Cost of Revenue) but rose to 92% in Q1 and Q2 2026 (10-Q 2026-06-30, MD&A Cost of Revenue) because lower-margin Otsuka inventory sales decreased; margin sustainability depends on geographic mix.
• Kezar acquisition adds contingent liability: $3.7M CVR liability recorded at June 30, 2026, with potential future payments tied to clinical development and disposition of zetomipzomib (10-Q 2026-06-30, Note 8).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Total revenue grew 34% YoY in 2024 ($235.1M vs $175.5M) and 20% in 2025 ($283.1M vs $235.1M) (10-K 2025-12-31, Consolidated Statements of Operations), driven by net product sales increasing 36% then 25% over the same periods. Quarterly YoY growth remains robust: Q2 2026 net product sales $79.4M vs $66.6M (+19%) and Q1 2026 $73.6M vs $60.0M (+23%) (10-Q 2026-06-30, Consolidated Statements of Operations; 10-Q 2026-03-31, Consolidated Statements of Operations). Operating income inflected from -$91.7M (2023) to -$4.7M (2024) to +$104.9M (2025) (10-K 2025-12-31, Consolidated Statements of Operations), with quarterly operating income reaching $46.3M (Q2 2026) and $41.4M (Q1 2026) versus $20.1M and $21.8M in the year-ago quarters (10-Q 2026-06-30, Consolidated Statements of Operations; 10-Q 2026-03-31, Consolidated Statements of Operations). R&D expense is rising as guided ($20.8M in 2024 → $32.5M in 2025 → $20.5M in H1 2026 vs $13.2M in H1 2025) (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations). SG&A declined sharply in 2025 ($172.0M → $101.8M) due to restructuring and lower share-based compensation, and has been roughly flat in 2026 YTD ($45.5M vs $46.4M) (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations). The 2025 net income surge to $287.2M is primarily a $173.0M tax benefit; excluding that, the operating trajectory is clearly improving.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Operating cash flow turned positive in 2024 ($44.4M) after -$33.5M in 2023, then jumped to $135.7M in 2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows). First-half 2026 operating cash flow reached $85.1M, up 87% from $45.5M in H1 2025 (10-Q 2026-06-30, Consolidated Statements of Cash Flows), with Q1 2026 alone generating $32.6M versus $1.3M in Q1 2025 (10-Q 2026-03-31, Consolidated Statements of Cash Flows). The improvement reflects higher net income (before the 2025 tax benefit), favorable working capital movements (accounts receivable, inventory, accrued liabilities), and lower cash restructuring outflows. Investing cash flows were modestly negative in 2025 (-$32.8M) and positive in H1 2026 (+$63.4M, including $5.2M net cash acquired from Kezar) (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). Financing cash outflows are dominated by share repurchases: $98.2M in 2025, $74.9M in H1 2026, and $36.2M in Q1 2026 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows; 10-Q 2026-03-31, Consolidated Statements of Cash Flows). Despite buybacks, total cash, equivalents, and investments rose from $358.5M (Dec 2024) to $398.0M (Dec 2025) to $443.1M (June 2026) (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A; 10-Q 2026-03-31, MD&A).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total assets grew from $550.6M (Dec 2024) to $751.6M (Dec 2025) to $792.3M (June 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets), driven by cash/investments ($358.5M → $398.0M → $443.1M) and the 2025 deferred tax asset recognition of $176.2M (10-K 2025-12-31, Consolidated Balance Sheets). The finance lease liability (Monoplant) declined from $72.6M (Dec 2024) to $68.8M (Dec 2025) to $60.4M (June 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets), with scheduled payments continuing through 2030. Total liabilities were relatively flat at $173.2M (Dec 2024), $170.3M (Dec 2025), and $177.4M (June 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets), with the June 2026 increase partly from $23.1M deferred tax benefits liability assumed in the Kezar acquisition (10-Q 2026-06-30, Note 8). Shareholders' equity rose from $377.5M to $581.3M to $614.9M over the same dates, reflecting net income accumulation and share repurchases that reduced common shares outstanding from 140.9M to 132.3M to 132.9M (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets; 10-Q 2026-03-31, Consolidated Balance Sheets). No near-term debt maturities exist beyond the finance lease; the company states it expects to fund operations from existing cash and operating cash flows (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).

6. Data Gaps

• Full quarterly results for Q3 2025 and Q4 2025 (the 10-Q for Q3 2025 is truncated in the provided documents; no separate Q4 10-Q filing is included).
• Full-year 2026 results (only H1 2026 is available).
• Detailed quarterly breakdown of 2023 results for YoY quarterly comparison prior to 2024.
• Segment reporting beyond geographic splits (U.S. vs Japan) for net product sales.
• Complete schedule of long-term contractual obligations beyond the finance lease (the 10-K references Note 5 for material cash requirements but the note text is not in the provided excerpt).
• Off-balance sheet arrangements (the 10-Q states none exist, but the full disclosure is not in the provided text).